Assessment of the Efficacy of E. Coli 5C in the Management of Post-Colonoscopy Symptoms
Assessment of the Efficacy of E. Coli 5C in the Management of Post-colonoscopy Symptoms: a Randomised, Double-blind, Placebo-controlled Trial.
This prospective, randomized, double-blind, placebo-controlled clinical trial will evaluate the efficacy and safety of Escherichia coli 5C (Colipral®) in adult patients undergoing diagnostic colonoscopy. Participants will be randomized in a 1:1 ratio to receive either Colipral® or placebo for 14 days immediately after colonoscopy. The study aims to determine whether Colipral® reduces post-colonoscopy gastrointestinal symptoms compared with placebo, using validated symptom and stool assessment tools, patient-reported global improvement, and safety monitoring.
Studieöversikt
Status
Betingelser
Intervention / Behandling
Detaljerad beskrivning
Patients undergoing diagnostic colonoscopy may experience gastrointestinal discomfort in the days following the procedure, which may be related to alterations in the intestinal microbiota induced by bowel preparation. This study is designed to evaluate whether supplementation with Escherichia coli 5C (Colipral®) can reduce post-colonoscopy gastrointestinal symptoms compared with placebo.
This is a prospective, randomized, double-blind, placebo-controlled clinical trial. Adult patients undergoing complete diagnostic colonoscopy will be screened according to predefined inclusion and exclusion criteria and enrolled after written informed consent. Participants will be randomly assigned in a 1:1 ratio to receive either Colipral® or placebo for 14 days immediately following colonoscopy. The study treatment will be administered as 2 capsules per day, with 1 capsule in the morning and 1 capsule in the evening after dinner.
Clinical assessments will be performed at baseline and at 48 hours, 7 days, and 14 days after colonoscopy, with patient global impression of change and clinically relevant improvement assessed only at Day 7 and Day 14. The primary efficacy endpoint is the between-group difference in change in Gastrointestinal Symptom Rating Scale (GSRS) total score from baseline to Day 14. Secondary assessments include numerical rating scale (NRS) symptom scores, stool consistency, bowel movement frequency, patient global impression of change, clinically relevant improvement in gastrointestinal symptoms, use of rescue medication, treatment adherence, tolerability, and adverse events.
The study is designed to assess both the clinical efficacy and safety of Colipral® in the management of post-colonoscopy symptoms in adult patients.
Studietyp
Inskrivning (Beräknad)
Fas
- Inte tillämpbar
Kontakter och platser
Studiekontakt
- Namn: Davide Sisti, PhD
- Telefonnummer: +39 0722 303301
- E-post: davide.sisti@uniurb.it
Studieorter
-
-
-
Roma, Italien, 00191
- Clinica ARS Biomedica - Via Luigi Bodio 58
-
Kontakt:
- Dr. Fabrizio Ficuccilli's, MD
- Telefonnummer: +39 06 3614941
- E-post: info@arsbiomedica.it
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- Aged between 18 and 80 years;
- Must have undergone a full colonoscopy on the date of enrolment.
Exclusion Criteria:
- Chronic Inflammatory Bowel Disease
- Complicated Diverticular Disease (DICA classification >3)
- Neoplastic disease of the colon
- Diagnosed microscopic colitis
- Therapeutic colonoscopy
- Immunocompromised patients (primary immunodeficiency, cancer undergoing active chemotherapy or immunotherapy, autoimmune disease undergoing immunosuppressive treatment)
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Fyrdubbla
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: Escherichia coli 5C (Colipral®)
Participants in this arm will receive Colipral® (dietary supplement containing Escherichia coli 5C), administered twice daily, with 1 capsule in the morning and 1 capsule in the evening after dinner, for 14 days immediately following colonoscopy. |
Dietary supplement containing Escherichia coli 5C (Colipral®) |
|
Placebo-jämförare: Placebo
Participants in this arm will receive placebo, identical in appearance but not containing the probiotic strain, administered twice daily, with 1 capsule in the morning and 1 capsule in the evening after dinner, for 14 days immediately following colonoscopy. |
Matching placebo |
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Change in Gastrointestinal Symptom Rating Scale (GSRS) total score at Day 14
Tidsram: Baseline to Day 14 after colonoscopy
|
Between-group difference in change in gastrointestinal symptom severity from baseline to Day 14 after colonoscopy, assessed using the Gastrointestinal Symptom Rating Scale (GSRS). |
Baseline to Day 14 after colonoscopy
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Change in abdominal pain intensity score
Tidsram: 48 hours, Day 7, and Day 14 after colonoscopy
|
Between-group difference in abdominal pain intensity assessed using a Numerical Rating Scale (NRS, 0-10), with higher scores indicating greater symptom intensity, at 48 hours, Day 7, and Day 14 after colonoscopy. |
48 hours, Day 7, and Day 14 after colonoscopy
|
|
Change in abdominal bloating intensity score
Tidsram: 48 hours, Day 7, and Day 14 after colonoscopy
|
Between-group difference in abdominal bloating intensity assessed using a Numerical Rating Scale (NRS, 0-10), with higher scores indicating greater symptom intensity, at 48 hours, Day 7, and Day 14 after colonoscopy. |
48 hours, Day 7, and Day 14 after colonoscopy
|
|
Change in flatulence intensity score
Tidsram: 48 hours, Day 7, and Day 14 after colonoscopy
|
Between-group difference in flatulence intensity assessed using a Numerical Rating Scale (NRS, 0-10), with higher scores indicating greater symptom intensity, at 48 hours, Day 7, and Day 14 after colonoscopy. |
48 hours, Day 7, and Day 14 after colonoscopy
|
|
Change in stool consistency assessed by Bristol Stool Form Scale
Tidsram: 48 hours, Day 7, and Day 14 after colonoscopy
|
Between-group difference in stool consistency assessed using the Bristol Stool Form Scale at 48 hours, Day 7, and Day 14 after colonoscopy. |
48 hours, Day 7, and Day 14 after colonoscopy
|
|
Change in frequency of bowel movements
Tidsram: 48 hours, Day 7, and Day 14 after colonoscopy
|
Between-group difference in the mean number of daily bowel movements recorded at 48 hours, Day 7, and Day 14 after colonoscopy. |
48 hours, Day 7, and Day 14 after colonoscopy
|
|
Global Assessment of Change of Gastrointestinal Symptoms (PGIC) score at Day 7 and Day 14
Tidsram: Day 7 and Day 14 after colonoscopy
|
Between-group difference in the Global Assessment of Change of Gastrointestinal Symptoms at Day 7 and Day 14, measured using the Patient Global Impression of Change (PGIC), a 7-category ordinal scale ranging from "Very much worse" to "Very much improved". |
Day 7 and Day 14 after colonoscopy
|
|
Proportion of participants with clinically relevant improvement in gastrointestinal symptoms
Tidsram: Day 7 and Day 14 after colonoscopy
|
Proportion of participants with clinically relevant improvement in gastrointestinal symptoms, defined as a PGIC response of "Improved", assessed at Day 7 and Day 14 after colonoscopy. |
Day 7 and Day 14 after colonoscopy
|
|
Use of rescue medication for gastrointestinal symptoms
Tidsram: Within 14 days after colonoscopy
|
Proportion of participants who used concomitant or rescue medication for control of gastrointestinal symptoms within 14 days after colonoscopy. Type of drug, days of intake, and dose will also be recorded. |
Within 14 days after colonoscopy
|
|
Frequency of adverse events
Tidsram: Within 14 days after colonoscopy
|
Frequency and type of adverse events reported within 14 days after colonoscopy, including suspected allergic symptoms, nausea, vomiting, and other clinically relevant events. |
Within 14 days after colonoscopy
|
|
Treatment tolerability score
Tidsram: Day 14 after colonoscopy
|
Treatment tolerability assessed using a numerical score from 0 to 10 during the 14-day post-colonoscopy period. |
Day 14 after colonoscopy
|
|
Adherence to treatment
Tidsram: Within 14 days after colonoscopy
|
Adherence to study treatment, expressed as the percentage of doses taken compared with those expected during the 14-day observation period. |
Within 14 days after colonoscopy
|
Samarbetspartners och utredare
Samarbetspartners
Studieavstämningsdatum
Studera stora datum
Studiestart (Beräknad)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Andra studie-ID-nummer
- 139_16luglio2025_COLIPRAL_SIST
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .